Rep. Jared Moskowitz (D-FL) Buys Gilead Sciences (GILD) Stock
Jared Moskowitz made a stock purchase in Gilead Sciences, reflecting his support for the biopharmaceutical sector.
Reviewed by automated data checks against the source filing. How we make and check alerts
Rep. Jared Moskowitz (D-FL) bought between $1,001 and $15,000 of Gilead Sciences, Inc. ($GILD) stock on May 6, 2026. The trade was disclosed in a STOCK Act periodic transaction report filed June 19, 2026.
Since the trade, $GILD is down 2.4% after 1 week, down 5.2% after 1 month and up 16.0% to date (from the $134.65 close on May 6, 2026).
Financial Disclosure Report
Clerk of the House of Representatives • Legislative Resource Center • B81 Cannon Building • Washington, DC 20515
Filer Information
- Name:
- Rep. Jared Moskowitz (D-FL)
- Status:
- Member — House
- State/District:
- FL-23
- Party:
- Democrat
Filing Information
- Filing Type:
- Periodic Transaction Report
- Filing Year:
- 2026
- Filing Date:
- Jun 19, 2026
Schedule B: Transactions
| Asset | Transaction | Date | Amount |
|---|---|---|---|
| Gilead Sciences, Inc. ($GILD) | Buy | May 6, 2026 | $1,001 - $15,000 |
Summary of the filed report, not the original document. Find the original: House financial disclosure search
GILD
Gilead Sciences, Inc.
Key Points
- On May 6, 2026, Jared Moskowitz purchased shares of Gilead Sciences valued between $1,001 and $15,000.
- Gilead Sciences, which specializes in innovative medicines, has a market cap of about $186.7 billion and a recent close of $150.11.
- Analysts maintain a positive outlook on Gilead, with a consensus buy rating and a mean price target of $158.15.
Get $GILD trade alerts by text
We text you when insiders, Congress or big funds trade $GILD. Free.
Not investment advice. EarningsIQ is not a registered investment adviser, and this automated Gilead Sciences, Inc. alert may contain errors. Disclosures
Moskowitz's Stock Purchase
On May 6, 2026, Jared Moskowitz, a Democrat in the House representing Florida's 23rd district, bought shares of Gilead Sciences, Inc. (GILD) valued between $1,001 and $15,000. This transaction was reported on June 19, 2026, as part of the disclosures required under the STOCK Act.
Jared Moskowitz vs. the S&P 500
Hypothetical returns from Jared Moskowitz's disclosed trades, not real profit or advice. How we model this.
What This Means for Gilead
Moskowitz's purchase adds to the attention on Gilead Sciences as it continues to develop and commercialize important medicines. The company is known for its treatments in areas of unmet medical need, including HIV and COVID-19 therapies. His investment reflects a potentially strong belief in the future of the biopharmaceutical sector, especially given Gilead's significant market presence with a market cap of approximately $186.7 billion.
Institutional Activity
While there are no recent reports of other funds making moves with Gilead shares, previous coverage noted that Caisse de Depot Et Placement Du Quebec increased its stake in Gilead by 62.6%, adding 594,774 shares, and Massachusetts Financial Services boosted its holdings by 48.7%, adding over 2 million shares. This institutional support suggests confidence in Gilead's future prospects.
How Gilead Sciences, Inc. Stock Has Traded
As of the last close on Friday, Gilead's stock stood at $150.11, which is in the middle of its 52-week range of $108.46 to $157.29. The stock is trading above its 50-day moving average of approximately $139.97, indicating a positive trend in recent trading.
Recent Earnings
In its most recent earnings report, Gilead Sciences reported revenue of about $30.46 billion, with a revenue growth of 10.2%. However, it posted a loss per share of $2.66, reflecting ongoing challenges in profitability. The next earnings report is scheduled for October 29, 2026.
Insider Buying and Selling at Gilead Sciences, Inc.
On June 15, 2026, Gilead's Chief Communications and Corporate Affairs Officer, Johanna Mercier, sold 3,000 shares at an average price of $123.92, totaling about $371,771.70. Additionally, CFO Andrew Dickinson sold 3,000 shares at an average price of $125.40, amounting to around $376,200. Both transactions were part of planned sales and do not indicate negative sentiment towards the company.
Analysts Set New Price Targets
Gilead has received various analyst ratings recently. On October 8, 2026, RBC Capital maintained a 'Sector Perform' rating with a target price of $126. Cantor Fitzgerald reiterated an 'Overweight' rating, also on October 8, with a target of $155. Truist Securities and JP Morgan have maintained 'Buy' and 'Overweight' ratings, respectively, with targets ranging from $158 to $170. The consensus among analysts is a strong buy rating, reflecting confidence in Gilead's future performance.
What Gilead Sciences, Inc. Does
Gilead Sciences, based in Foster City, California, focuses on discovering and developing innovative medicines for serious diseases. Its work in HIV, hepatitis, and COVID-19 treatments positions it as a key player in the healthcare industry, especially as healthcare needs evolve.
What's Ahead for Gilead Sciences, Inc.
Investors will be watching for Gilead's next earnings report on October 29, 2026, to gauge its financial health and outlook. As a reminder, Moskowitz's stock purchase reflects his commitment to the healthcare sector, particularly in a company with a significant impact on public health. This 13F filing shows his holdings as of the reporting period and may not represent his current position.
Related Filing Alerts
Source: Jared Moskowitz's STOCK Act disclosure on $GILD (May 6, 2026). Find the original filing: House financial disclosure search. Written by software, not financial advice. How we make alerts